Grasim Inds Share Price Live Updates: Grasim Industries Trading Update
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Profit by knowlytics
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
HFCL shares witnessed an uptick on Friday after the company secured a Rs 496 crore overseas order for data centre connectivity solutions, extending their 220% rally in 2026. With a record order book, rising exports and growing AI, defence and telecom opportunities, analysts remain optimistic about the company’s long-term growth prospects.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Vedanta Group stocks experienced significant gains on Friday after their recent demerger. Vedanta Iron and Steel shares surged five percent, hitting the upper circuit limit. Vedanta Oil and Gas shares also saw a substantial increase, extending recent positive momentum. Vedanta Power and Vedanta Aluminium reported production and sales figures for the first quarter. Analysts at…
Dr Reddy’s Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product due to a quality-related API issue. While brokerages remain broadly positive on the long-term outlook, several have cut target prices and earnings estimates, citing near-term execution risks and slower product ramp-up.